Howard Horn

October 16, 2026

RARE FDA approves Fayuvi, triggers $203M voucher sale. Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.

October 14, 2026

Vir Biotechnology Secures $1.875B Gilead Deal for Cancer Drug Candidates. Vir Biotechnology entered a $1.875 billion partnership with Gilead that includes an upfront cash payment and shares, plus up to $1.785 billion in milestone payments and royalties. The collaboration also covers three PRO‑XTEN dual‑masked T‑cell engager candidates for solid tumors, with one, VIR‑5500, receiving FDA Fast‑Track status for metastatic castration‑resistant prostate cancer. These developments expand Vir’s oncology pipeline and strengthen its relationship with a major biopharma partner.